Skip to content

Released Nov 5, 2021, before the open

10-Q filed Nov 5, 2021, 36 days after period end · 0001764013-21-000119

Q2 2022 · 10-Q
Revenue—
Net Income-$37.70Mno prior Q2 2021 on fileN/M vs Q1 2022
EPS Diluted-$0.35no prior Q2 2021 on fileN/M vs Q1 2022
Operating Cash Flowderived-$20,047,000—
Free Cash Flowderived-$20,091,000—

What the release said

The release

Same quarter

MetricQ2 2022Q2 2018
Net Income-$37.70M-$6.35M
EPS Diluted-$0.35—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR